Elgendy Islam Y, Mahmoud Ahmed, Conti Charles R
Department of Medicine, University of Florida, 1600 SW Archer Road, PO BOX 100277, Gainesville, FL, 32610; USA.
Recent Pat Cardiovasc Drug Discov. 2014;9(1):11-21. doi: 10.2174/1574890109666140901144210.
Beta-adrenergic blockers remain one of the cornerstones in the management of coronary artery disease, both in chronic stable angina and myocardial infarction. These recommendations were based on studies conducted in the era prior to the establishment of the modern therapy for ischemic heart disease and myocardial infarction i.e. anti-platelet therapy, statins, and percutaneous coronary interventions. Recent studies emerged questioning the beneficial effect of beta-blockers in the management of patients with stable ischemic heart disease and myocardial infarction. In this review, we will discuss briefly the pharmacology of beta-blockers along the evidence that supports the use of beta-blockers in the management of stable ischemic heart disease and myocardial infarction. The recent studies questioning its use will also be discussed.
β受体阻滞剂仍然是冠心病管理的基石之一，无论是在慢性稳定型心绞痛还是心肌梗死方面。这些建议是基于在现代缺血性心脏病和心肌梗死治疗方法（即抗血小板治疗、他汀类药物和经皮冠状动脉介入治疗）建立之前的时代所进行的研究。最近出现的研究对β受体阻滞剂在稳定型缺血性心脏病和心肌梗死患者管理中的有益作用提出了质疑。在本综述中，我们将简要讨论β受体阻滞剂的药理学，以及支持在稳定型缺血性心脏病和心肌梗死管理中使用β受体阻滞剂的证据。同时也将讨论最近质疑其使用的研究。
